Market Overview

Inovio Says Study Shows Robust Vaccine Antibody Response; Positive Results on Leukemia DNA Vaccine

Related INO
Race for Vaccines, Treatments as West Africa Ebola Death Toll Tops 100
Mid-Afternoon Market Update: Inovio Rallies on Vaccine Award; Citigroup Remains Down on Stress Test Results

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that preliminary results of a phase II clinical trial to treat leukemia with a WT1 DNA vaccine delivered with Inovio's proprietary electroporation delivery system showed robust vaccine-specific antibody responses in all vaccinated subjects evaluated to date. Furthermore, T cell immune responses, including those of the "killer T cells," were detected. Antibody and T cell responses are strong signals of the DNA vaccine's potential to treat the disease.

Posted-In: News FDA Legal

 

Most Popular

Related Articles (INO)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free